Keyphrases
5-fluorouracil (5-FU)
22%
Advanced Gastric Cancer
65%
Aging
20%
Chemotherapy
44%
Cisplatin
32%
DNA Methylation (DNAm)
31%
Docetaxel
25%
Endoscopic Retrograde Cholangiopancreatography
11%
Endoscopic Submucosal Dissection
14%
Endoscopic Ultrasound-guided Fine-needle Aspiration (EUS-FNA)
15%
Epigenetic Field Defect
15%
Epigenetic Modification
27%
Epigenetics
12%
Fluoropyrimidine
24%
Gastric Cancer
52%
Gastric Cancer Patients
13%
Gastric Carcinoma
15%
Gastric mucosa
35%
Gastrointestinal Cancer
14%
Gastrointestinal Stromal Tumor
29%
Genetic Modification
12%
Healthy Volunteers
12%
Helicobacter Pylori (H. pylori)
44%
Helicobacter Pylori Infection
19%
Hippocampus
12%
Irinotecan
24%
Japan
13%
Median Overall Survival
14%
Median Progression-free Survival
20%
Metastatic Colorectal Cancer (mCRC)
17%
Metastatic Gastric Cancer
12%
Methylation
34%
Methylation Status
34%
Mitomycin C
11%
Monotherapy
15%
Multicenter Retrospective Study
15%
Neurogenesis
12%
Neutropenia
13%
Nivolumab
17%
Overall Survival
11%
Phase II Study
13%
Phase II Trial
12%
Preventive Effect
12%
Radiofrequency Ablation
11%
Ramucirumab
15%
S-1 Plus Cisplatin
12%
Second-line Chemotherapy
13%
Shakuyakukanzoto
16%
Trifluridine-tipiracil
17%
Tumor
22%
Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Cancer
100%
Acute Pancreatitis
7%
Adverse Event
24%
Amrubicin
7%
Ascites
8%
Bevacizumab
7%
Chemotherapy
66%
Cisplatin
26%
Clinical Trial
12%
Combination Therapy
10%
Constipation
13%
Diarrhea
14%
Digestive System Cancer
9%
Disease
8%
Docetaxel
18%
First-Line Chemotherapy
10%
Fluoropyrimidine
24%
Fluorouracil
17%
Folinic Acid
8%
Gastric Mucosa
17%
Gastrointestinal Stromal Tumor
11%
Helicobacter Infection
11%
Helicobacter Pylori
23%
Imatinib
11%
Immune Checkpoint Inhibitor
7%
Infection
7%
Inflammatory Bowel Disease
7%
Irinotecan
22%
Liver Metastasis
7%
Malignant Neoplasm
26%
Metastatic Colorectal Cancer
14%
microRNA
11%
Mitomycin
11%
Monotherapy
16%
Neoplasm
13%
Neuroendocrine Carcinoma
11%
Neurotoxicity
8%
Nivolumab
13%
Normal Human
15%
Overall Survival
24%
Oxaliplatin
12%
Paclitaxel
12%
Pancreatitis
6%
Placebo
7%
Progression Free Survival
26%
Ramucirumab
15%
Retrospective Study
22%
Second-Line Chemotherapy
11%
Tipiracil
11%
Trifluridine
11%
Medicine and Dentistry
Abdominal Cancer
72%
Arm
21%
Ascites
8%
Biopsy Technique
10%
Cancer Risk
7%
Chemotherapy
43%
Cisplatin
15%
Clinical Trial
10%
Colorectal Carcinoma
11%
Constipation
8%
Diagnosis
7%
DNA Methylation
11%
DNA Mismatch Repair
11%
Docetaxel
8%
Duodenum
7%
Endoscopic Retrograde Cholangiopancreatography
11%
Endoscopic Submucosal Dissection
14%
Endoscopic Ultrasound
12%
Endoscopic Ultrasound Guided Fine Needle Biopsy
16%
Endoscopy
8%
Esophageal Squamous Cell Carcinoma
8%
Fine-Needle Aspiration
11%
First-Line Chemotherapy
7%
Fluorouracil
8%
Gastrointestinal Stromal Tumor
11%
Gene Mutation
8%
Helicobacter Infection
7%
Helicobacter Pylori
20%
Malignant Neoplasm
20%
Metastatic Carcinoma
7%
Methylation
20%
Microsatellite Instability
9%
Neoplasm
27%
Neuroendocrine Tumor
10%
Neutropenia
7%
Nivolumab
17%
Overall Survival
14%
Pancreas Cancer
11%
Progression Free Survival
15%
Promoter Region
7%
Quality of Life
8%
Radiofrequency Ablation
13%
Ramucirumab
9%
Retrospective Study
12%
Stenting
7%
Stomach Mucosa
10%
Thyroid Cancer
11%
Tipiracil
17%
Trifluridine
17%
Ulcer
8%